Citations

Showing 10 of 108081 citations.

Digital Health: A New Frontier
Barracca, Antonio, Ledda, Stefano, Mancosu, Gianmaria, Quintaliani, Giuseppe, Kashani, Kianoush , Kashani, Kianoush B , Ledda, Stefano, Mancosu, Gianmaria, Pintore, Giovanni , Ronco, Claudio

Mayo Clinic

Journal of Translational Critical Care Medicine | April 12, 2023 | Volume: 5 | Issue: 2 | Pages: No page available

10.4103/jtccm-d-22-00018 Get It

ABSTRACT The Food and Drug Administration defines digital health (DH) as “a convergence of people, information, technology, and connectivity to improve health care and health outcomes”. Information and communication technologies are categorized under the DH umbrella. While still in their infancy, these technologies have great potential to revolutionize the clinical approaches to bedside management and overall health care. Over the past few decades, there has been a substantial improvement in the technology in smart wearable devices that enabled them to enhance their abilities to collect patient-related data, including physiological and behavioral information in the Internet of things. This has resulted in implementing several controlled clinical trials that have confirmed their validity and safety. These digital diagnostics have led to the expansion of digital therapies and specialized software (for example, apps) capable of effectively and measurably guiding patients’ progress toward improving their clinical condition. These technologies are clinically validated treatments for many diseases with particular effectiveness in pathological conditions related to behavior and psychological factors. In this review paper, we describe the outlines of some of the recent progress made in this field.
Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
Morcos, Peter N. , Schlender, Jan, Burghaus, Rolf , Moss, Jonathan, Lloyd, Adam , Childs, Barrett H. , Macy, Margaret E. , Chung, John, Garmann, Dirk , Schlender, Jan‐Frederik , Moss, Jonathan, Reid, Joel M.

Mayo Clinic

Clinical and Translational Science | April 12, 2023 | Volume: 16 | Issue: 7 | Pages: 1197-1209

10.1111/cts.13523 | PMID 37042099 Get It

AbstractCopanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m2 for pediatric patients ≥1 year old, corresponding to 80% of the adult recommended dose adjusted for body surface area. An adult physiologically based pharmacokinetic (PBPK) model was initially established using copanlisib physicochemical and disposition properties and clinical pharmacokinetics (PK) data and was shown to adequately capture clinical PK across a range of copanlisib doses in adult cancer patients. The adult PBPK model was then extended to the pediatric population through incorporation of age‐dependent anatomical and physiological changes and used to simulate copanlisib exposures in pediatric cancer patient age groups. The pediatric PBPK model predicted that the copanlisib 28 mg/m2 dose would achieve similar copanlisib exposures across pediatric ages when compared with historical adult exposures following the approved copanlisib 60 mg dose administered on Days 1, 8, and 15 of a 28‐day cycle. Clinical PK were collected from a phase I study in pediatric patients with relapsed/refractory solid tumors (aged ≥4 years). An established adult population PK model was extended to incorporate an allometrically‐scaled effect of body surface area and confirmed that the copanlisib maximum tolerated dose of 28 mg/m2 was appropriate to achieve uniform copanlisib exposures across the investigated pediatric age range and consistent exposures to historical data in adult cancer patients. The model‐informed approach successfully supported and confirmed the copanlisib pediatric dose recommendation.
Cellular senescence in skin‐related research: Targeted signaling pathways and naturally occurring therapeutic agents
Polańska, Adriana , Stawny, Maciej , Rubiś, Błażej, Nourredine, Sarah, Ashiqueali, Sarah , Schneider, Augusto , Wyles, Saranya P. , Kirkland, James L. , Tchkonia, Tamara, Masternak, Michal M , Ashiqueali, Sarah A , Dańczak‐Pazdrowska, Aleksandra , Gornowicz‐Porowska, Justyna , Krajka‐Kuźniak, Violetta , Gostyńska, Aleksandra , Rubiś, Błażej, Tchkonia, Tamar

Mayo Clinic

Aging Cell | April 12, 2023 | Volume: 22 | Issue: 6 | Pages: No page available

10.1111/acel.13845 | PMID 37042069 Get It

AbstractDespite the growing interest by researchers into cellular senescence, a hallmark of cellular aging, its role in human skin remains equivocal. The skin is the largest and most accessible human organ, reacting to the external and internal environment. Hence, it is an organ of choice to investigate cellular senescence and to target root‐cause aging processes using senolytic and senomorphic agents, including naturally occurring plant‐based derivatives. This review presents different aspects of skin cellular senescence, from physiology to pathology and signaling pathways. Cellular senescence can have both beneficial and detrimental effects on the skin, indicating that both prosenescent and antisenescent therapies may be desirable, based on the context. Knowledge of molecular mechanisms involved in skin cellular senescence may provide meaningful insights for developing effective therapeutics for senescence‐related skin disorders, such as wound healing and cosmetic skin aging changes.
Pie‐Net: Prior‐information‐enabled deep learning noise reduction for coronary CT angiography acquired with a photon counting detector CT
Chang, Shaojie , Huber, Nathan R. , Marsh, Jeffrey F., Koons, Emily K. , Gong, Hao , Yu, Lifeng , Yu, Lifeng , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Medical Physics | April 12, 2023 | Volume: 50 | Issue: 10 | Pages: 6283-6295

10.1002/mp.16411 | PMID 37042049 Get It

AbstractBackgroundPhoton‐counting‐detector CT (PCD‐CT) enables the production of virtual monoenergetic images (VMIs) at a high spatial resolution (HR) via simultaneous acquisition of multi‐energy data. However, noise levels in these HR VMIs are markedly increased.PurposeTo develop a deep learning technique that utilizes a lower noise VMI as prior information to reduce image noise in HR, PCD‐CT coronary CT angiography (CTA).MethodsCoronary CTA exams of 10 patients were acquired using PCD‐CT (NAEOTOM Alpha, Siemens Healthineers). A prior‐information‐enabled neural network (Pie‐Net) was developed, treating one lower‐noise VMI (e.g., 70 keV) as a prior input and one noisy VMI (e.g., 50 keV or 100 keV) as another. For data preprocessing, noisy VMIs were reconstructed by filtered back‐projection (FBP) and iterative reconstruction (IR), which were then subtracted to generate “noise‐only” images. Spatial decoupling was applied to the noise‐only images to mitigate overfitting and improve randomization. Thicker slice averaging was used for the IR and prior images. The final training inputs for the convolutional neural network (CNN) inside the Pie‐Net consisted of thicker‐slice signal images with the reinsertion of spatially decoupled noise‐only images and the thicker‐slice prior images. The CNN training labels consisted of the corresponding thicker‐slice label images without noise insertion. Pie‐Net's performance was evaluated in terms of image noise, spatial detail preservation, and quantitative accuracy, and compared to a U‐net‐based method that did not include prior information.ResultsPie‐Net provided strong noise reduction, by 95 ± 1% relative to FBP and by 60 ± 8% relative to IR. For HR VMIs at different keV (e.g., 50 keV or 100 keV), Pie‐Net maintained spatial and spectral fidelity. The inclusion of prior information from the PCD‐CT data in the spectral domain was able to improve a robust deep learning‐based denoising performance compared to the U‐net‐based method, which caused some loss of spatial detail and introduced some artifacts.ConclusionThe proposed Pie‐Net achieved substantial noise reduction while preserving HR VMI's spatial and spectral properties.
The First Survival Score for Patients Treated with Whole-Brain Radiotherapy Plus Simultaneous Integrated Boost for Brain Metastases
Rades, Dirk , JOHANNWERNER, LEONIE, Werner, Elisa, Cremers, Florian , Yu, Nathan Y. , Yu, Nathan

Mayo Clinic

Biology | April 12, 2023 | Volume: 12 | Issue: 4 | Pages: 585

10.3390/biology12040585 | PMID 37106785 Get It

A modern approach for brain metastases includes whole-brain radiotherapy plus simultaneous boost (WBRT+SIB). We developed a survival score in 128 patients treated with WBRT+SIB. Three models, each including three prognostic groups, were created. Positive predictive values (PPVs) for death ≤6 and survival ≥6 months were calculated. On multivariate analyses, performance score (KPS) and the number of brain metastases were significantly associated with survival. On univariate analyses, age showed a strong trend, and extra-cerebral cranial metastases a trend. In Model 1 (KPS, number of lesions), compared groups had 6-month survival rates of 15%, 38% and 57%. In Model 2 (KPS, lesions, age), rates were 17%, 33% and 75%, and in Model 3 (KPS, lesions, age, extra-cerebral metastases), 14%, 34% and 78%. PPVs for death ≤6 and survival ≥6 months were 85% and 57% (Model 1), 83% and 75% (Model 2), and 86% and 78% (Model 3). Thus, all models were accurate in predicting death ≤ 6 months; poor-prognosis patients may not benefit from SIB. Models 2 and 3 were superior in predicting survival ≥ 6 months. Given that Model 3 requires more data (including extensive staging), Model 2 is considered favorable for many patients. If extra-cerebral metastases are already known or extensive staging has been performed, Model 3 can also be used.
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms
Dueck, Amylou C. , Palmer, Jeanne , Sproat, Lisa, Hashmi, Shahrukh K. , Mesa, Ruben A. , Litzow, Mark R. , Al‐Kali, Aref , Dueck, A. C. , Palmer, Jeanne M , Hashmi, Shahrukh K , Mesa, Ruben , Al-Kali, Aref , Tibes, Raoul , Kosiorek, Heidi , Bogenberger, James M. , Hogan, William J.

Mayo Clinic

Cancer | April 12, 2023 | Volume: 129 | Issue: 15 | Pages: 2321-2330

10.1002/cncr.34800 | PMID 37042080 Get It

AbstractBackgroundMyeloid neoplasms (myelodysplastic syndrome [MDS], myelofibrosis, and chronic myelomonocytic [CMML]) are aggressive hematological malignancies for which, despite recent approvals, novel therapies are needed to improve clinical outcomes. The hedgehog (HH) pathway is one of the main pathways for cancer stem cells survival and several HH inhibitors (HHi) are approved in clinical practice.MethodsSonidegib (SON), an oral HHi, was tested in this phase 1/1b trial in combination with azacitidine (AZA, 75 mg/m2 days ×7) in patients with newly diagnosed and relapsed/refractory (r/r) chronic MN or acute myeloid leukemia (AML).ResultsSixty‐two patients (28 [45%] newly diagnosed) were treated in this study, including 10 patients in the dose‐finding component and 52 patients in phase 1b. SON 200 mg oral daily on days 1–28 each cycle was deemed the recommended dose for phase 1b. Out of 21 rrAML patients, two achieved response (one complete response/one morphologic leukemia‐free state) with no responses seen in seven r/r MDS/CMML patients. In newly diagnosed AML/MDS, response was seen in six (three had complete remission, two had morphological leukemia‐free status) of 27 patients. Median overall survival was 26.4 and 4.7 months for newly diagnosed MDS and AML, respectively. Safety was satisfactory with common (>20%) side effects including fatigue, constipation, nausea, cough, insomnia, and diarrhea. Only 7% of patients died in the study, and none of the deaths were deemed related to treatment.ConclusionsOur study shows that AZA + SON are a safe combination in a patient with MN. Similar to other hedgehog inhibitors, this combination yielded limited response rate in patients with myeloid neoplasms.
Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy
Driver‐Dunckley, Erika , Dunckley, Nathaniel, Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Tremblay, Cécilia , Beach, Thomas G. , Driver-Dunckley, Erika D., Zhang, Nan , Serrano, Geidy E. , Atri, Alireza , Adler, Charles H.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | April 11, 2023 | Volume: 82 | Issue: 5 | Pages: 438-451

10.1093/jnen/nlad025 | PMID 37040756 Get It

Abstract The objective of this study was to determine the prevalence, incidence, and clinical diagnostic accuracy for neuropathologically diagnosed progressive supranuclear palsy (PSP) with data from a longitudinal clinicopathological study using Rainwater criteria to define neuropathological PSP. Of 954 autopsy cases, 101 met Rainwater criteria for the neuropathologic diagnosis of PSP. Of these, 87 were termed clinicopathological PSP as they also had either dementia or parkinsonism or both. The prevalence of clinicopathologically defined PSP subjects in the entire autopsy dataset was 9.1%, while the incidence rate was estimated at 780 per 100 000 persons per year, roughly 50-fold greater than most previous clinically determined PSP incidence estimates. A clinical diagnosis of PSP was 99.6% specific but only 9.2% sensitive based on first examination, and 99.3% specific and 20.7% sensitive based on the final clinical exam. Of the clinicopathologically defined PSP cases, 35/87 (∼40%) had no form of parkinsonism at first assessment, while this decreased to 18/83 (21.7%) at final assessment. Our study confirms a high specificity but low sensitivity for the clinical diagnosis of PSP. The low clinical sensitivity for PSP is likely primarily responsible for previous underestimates of the PSP population incidence rate.
Development of a portable abdominal normothermic regional perfusion (A-NRP) program in the United States
Croome, Kristopher P. , Brown, Thomas E. , Mabrey, Richard L., Sonnenwald, Sherry L., Burns, Justin M. , Mao, Shennen A. , Clendenon, Jacob N. , Nguyen, Justin H. , Perry, Dana K. , Maddox, Rebecca G., Clendenon, Jacob , Taner, Burcin , Croome, Kris P , Mao, Shennen A , Taner, C. Burcin

Mayo Clinic

Liver Transplantation | April 11, 2023 | Volume: 29 | Issue: 12 | Pages: 1282-1291

10.1097/lvt.0000000000000156 | PMID 37040930 Get It

In situ abdominal normothermic regional perfusion (A-NRP) has been used for liver transplantation (LT) with donation after circulatory death (DCD) liver grafts in Europe with excellent results; however, adoption of A-NRP in the United States has been lacking. The current report describes the implementation and results of a portable, self-reliant A-NRP program in the United States. Isolated abdominal in situ perfusion with an extracorporeal circuit was achieved through cannulation in the abdomen or femoral vessels and inflation of a supraceliac aortic balloon and cross-clamp. The Quantum Transport System by Spectrum was used. The decision to use livers for LT was made through an assessment of perfusate lactate (q15min). From May to November 2022, 14 A-NRP donation after circulatory death procurements were performed by our abdominal transplant team (N = 11 LT, N = 20 kidney transplants, and 1 kidney-pancreas transplant). The median A-NRP run time was 68 minutes. None of the LT recipients had post-reperfusion syndrome, nor were there any cases of primary nonfunction. All livers were functioning well at the time of maximal follow-up with zero cases of ischemic cholangiopathy. The current report describes the feasibility of a portable A-NRP program that can be used in the United States. Excellent short-term post-transplant results were achieved with both livers and kidneys procured from A-NRP.
No Survival Benefit With Wide Margin Mohs Micrographic Surgery for Melanoma: A National Cancer Database Analysis
Liszewski, Walter , Vidal, Nahid Y. , Demer, Addison M. , O'Hern, Keegan , Demer, Addison, O’Hern, Keegan

Mayo Clinic

Dermatologic Surgery | April 11, 2023 | Volume: 49 | Issue: 7 | Pages: 704-705

10.1097/dss.0000000000003804 | PMID 37040492 Get It

Outcomes of Salvage Lymph Node Dissection for Prostate Cancer with Clinical Nodal Relapse: Results of a Multicentric, Retrospective Study
Oderda, Marco , Melloni, Guglielmo, Munegato, Stefania, Tosco, Lorenzo , Karnes, R. Jeffrey , Joniau, Steven , Falcone, Marco , Zattoni, Fabio , Gontero, Paolo

Mayo Clinic

European Medical Journal | April 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 108-115

10.33590/emj/10312647 Get It

Introduction: Salvage lymph node dissection (sLND) is a treatment option for prostate cancer (PCa) patients with nodal recurrence after radical therapy to delay tumour progression and hormonal treatment. We evaluated the outcomes in terms of biochemical recurrence (BCR), clinical regression, and cancer specific survival (CSS) in a large, multicentric series of patients treated with sLND for nodal recurrence of PCa. Methods: We retrospectively reviewed the records of 106 consecutive patients with BCR of PCa after radical treatment who underwent sLND between 2007 and 2013 at three tertiary centres. BCR was defined as prostate-specific antigen (PSA) >0.2 ng/mL. Clinical recurrence (CR) was defined as a positive imaging study or biopsy for metastasis after sLND. Kaplan–Meier curves calculated BCR-free survival (BFS), CR-free survival (CRS), and CSS. Cox regression analyses were performed to identify predictors of CR. Results: Median number of nodes removed at sLND was 21.7, with a median of three positive nodes. Immediate biochemical response after surgery was achieved in 50.9% of patients. At a median follow-up of 22.5 months, biochemical failure and CR were experienced by 67.9% and 40.5% of patients, respectively. At 2 years, BFS, CRS, and CSS were 25%, 52%, and 92%, respectively. Castrate-resistant prostate cancer (CRPC) status, PSA level at sLND, and presence of biochemical failure after sLND were significantly associated with CR after surgery. Conclusions: sLND represents a valid treatment option for selected patients with nodal recurrences, achieving a CR-free status in more than half of patients at 2 years. Patients with CRPC status or high PSA values might not be the best candidates for a sLND.